-+ 0.00%
-+ 0.00%
-+ 0.00%

NURIX THERAPEUTICS PRESENTS NEW TRANSLATIONAL DATA FROM FIRST-IN-HUMAN CLINICAL TRIAL OF ORAL CBL-B INHIBITOR NX-1607 DEMONSTRATING IMMUNE ACTIVATION AND TUMOR MICROENVIRONMENT REMODELING

Reuters·11/07/2025 14:00:15

Please log in to view news